… In patients with autoimmune disease, approximately 2–3 g of rituximab in total is given as a
series … Cambridge, G. et al. Serological changes following B lymphocyte depletion therapy for …

Objectives. An open study of B‐lymphocyte depletion was undertaken in rheumatoid
arthritis (RA) patients to test the hypothesis that B lymphocytes may be essential to disease …

Objective To gain preliminary evidence for the safety and efficacy of B lymphocyte depletion
therapy in refractory systemic lupus erythematosus (SLE). Methods Six female patients with …

Objective To study the quantitative and phenotypic reconstitution of peripheral blood B cells
and its relationship to the dynamics of clinical response in patients with rheumatoid arthritis (…

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis -
Cambridge - 2003 - Arthritis & Rheumatism - Wiley Online Library … Geraldine Cambridge PhD …

Objectives. To assess the clinical and basic serological consequences of B-cell depletion
with rituximab in the treatment of patients with systemic lupus erythematosus (SLE) who have …

Objectives: To obtain evidence for dose response and to extend evidence of safety and
efficacy for B lymphocyte depletion in rheumatoid arthritis. Methods: Twenty two patients with …

… 1g), which indicates that the platelet edges are not densely covered with a PI brush layer
but are available for epitaxial growth. The selective nature of the growth from the faces at the …

… A previous study by Cambridge et al (14) showed that antipneumococcal responses are
preserved after 1 cycle of BCDT in patients with SLE for at least 1 year. Two other adverse …

… Pretreatment serum anti-CCP antibody levels were elevated (>200 IU/ml) in 7 of the 10
patients tested (Figure 1G). Although they visually paralleled the changes in RF levels, the …